

Marcus Lettau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4227283/publications.pdf>

Version: 2024-02-01

44
papers

1,307
citations

304743

22
h-index

361022

35
g-index

44
all docs

44
docs citations

44
times ranked

1793
citing authors

#	ARTICLE	IF	CITATIONS
1	Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the α disintegrin and metalloproteases 10 and 17. <i>International Journal of Cancer</i> , 2013, 133, 1557-1566.	5.1	170
2	Nck adapter proteins: functional versatility in T cells. <i>Cell Communication and Signaling</i> , 2009, 7, 1.	6.5	89
3	Secretory lysosomes and their cargo in T and NK cells. <i>Immunology Letters</i> , 2007, 108, 10-19.	2.5	72
4	NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human $\gamma\delta$ T cells: Modulation by temozolomide and α disintegrin and metalloproteases 10 and 17 inhibitors. <i>Oncolmmunology</i> , 2016, 5, e1093276.	4.6	63
5	Insights into the molecular regulation of FasL (CD178) biology. <i>European Journal of Cell Biology</i> , 2011, 90, 456-466.	3.6	62
6	The adaptor protein Nck interacts with Fas ligand: Guiding the death factor to the cytotoxic immunological synapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5911-5916.	7.1	57
7	Binding of the Intracellular Fas Ligand (FasL) Domain to the Adaptor Protein PSTPIP Results in a Cytoplasmic Localization of FasL. <i>Journal of Biological Chemistry</i> , 2005, 280, 40012-40024.	3.4	51
8	Storage, Expression and Function of Fas Ligand, the Key Death Factor of Immune Cells. <i>Current Medicinal Chemistry</i> , 2008, 15, 1684-1696.	2.4	47
9	TGF- β 2 enhances the cytotoxic activity of $\gamma\delta$ T cells. <i>Oncolmmunology</i> , 2019, 8, e1522471.	4.6	43
10	Butyrophilin 3A/CD277-Dependent Activation of Human $\gamma\delta$ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. <i>Journal of Immunology</i> , 2016, 197, 3059-3068.	0.8	40
11	Considering Fas ligand as a target for therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 119-134.	3.4	37
12	Regulation of FasL expression: A SH3 domain containing protein family involved in the lysosomal association of FasL. <i>Cellular Signalling</i> , 2006, 18, 1327-1337.	3.6	37
13	The adapter protein Nck: Role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. <i>Protein Science</i> , 2010, 19, 658-669.	7.6	37
14	In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. <i>Oncolmmunology</i> , 2017, 6, e1358839.	4.6	37
15	Posttranslational regulation of Fas ligand function. <i>Cell Communication and Signaling</i> , 2008, 6, 11.	6.5	36
16	Effector Granules in Human T Lymphocytes: Proteomic Evidence for Two Distinct Species of Cytotoxic Effector Vesicles. <i>Journal of Proteome Research</i> , 2011, 10, 1603-1620.	3.7	33
17	Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes. <i>Molecular Immunology</i> , 2015, 65, 416-428.	2.2	33
18	2D DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells. <i>Proteomics</i> , 2008, 8, 2911-2925.	2.2	30

#	ARTICLE	IF	CITATIONS
19	Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the A Disintegrin and Metalloprotease 10 (ADAM10). <i>PLoS ONE</i> , 2014, 9, e102899.	2.5	26
20	Activation-dependent FasL expression in T lymphocytes and Natural Killer cells. <i>Signal Transduction</i> , 2004, 4, 206-211.	0.4	23
21	Effector granules in human T lymphocytes: the luminal proteome of secretory lysosomes from human T cells. <i>Cell Communication and Signaling</i> , 2011, 9, 4.	6.5	23
22	Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 168-176.	2.3	22
23	Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells. <i>Frontiers in Immunology</i> , 2019, 10, 569.	4.8	22
24	Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. <i>Cell Communication and Signaling</i> , 2013, 11, 41.	6.5	21
25	Immunosurveillance by human $\gamma\delta$ T lymphocytes: the emerging role of butyrophilins. <i>F1000Research</i> , 2017, 6, 782.	1.6	20
26	Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening. <i>BMC Immunology</i> , 2009, 10, 53.	2.2	18
27	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses $\gamma\delta$ T Cell Proliferation but Not Their Cytotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 1328.	4.8	16
28	Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 751-764.	5.4	15
29	FasL cross-linking inhibits activation of human peripheral T cells. <i>International Immunology</i> , 2009, 21, 587-598.	4.0	14
30	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. <i>PLoS ONE</i> , 2020, 15, e0239369.	2.5	14
31	SDF1 α -induced interaction of the adapter proteins Nck and HS1 facilitates actin polymerization and migration in T cells. <i>European Journal of Immunology</i> , 2015, 45, 551-561.	2.9	12
32	Granulysin species segregate to different lysosome-related effector vesicles (LREV) and get mobilized by either classical or non-classical degranulation. <i>Molecular Immunology</i> , 2019, 107, 44-53.	2.2	12
33	Mechanistic peculiarities of activation-induced mobilization of cytotoxic effector proteins in human T cells. <i>International Immunology</i> , 2018, 30, 215-228.	4.0	11
34	Intra- and Extracellular Effector Vesicles From Human T And NK Cells: Same-Same, but Different?. <i>Frontiers in Immunology</i> , 2021, 12, 804895.	4.8	11
35	The adapter proteins ADAP and Nck cooperate in T cell adhesion. <i>Molecular Immunology</i> , 2014, 60, 72-79.	2.2	10
36	The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells. <i>Cancers</i> , 2021, 13, 5947.	3.7	8

#	ARTICLE	IF	CITATIONS
37	Differential protein-protein interactions of full length human FasL and FasL fragments generated by proteolysis. <i>Experimental Cell Research</i> , 2014, 320, 290-301.	2.6	7
38	Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. <i>OncoImmunology</i> , 2022, 11, 2030021.	4.6	7
39	Bispecific antibodies in acute lymphoblastic leukemia therapy. <i>Expert Review of Hematology</i> , 2020, 13, 1211-1233.	2.2	4
40	Erroneous expression of NKG2D on granulocytes detected by phycoerythrin-conjugated clone 149810 antibody. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, , .	1.5	4
41	CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 698503.	3.7	4
42	FasL associated factors and their potential role in the regulation of FasL expression. <i>Signal Transduction</i> , 2005, 5, 195-201.	0.4	3
43	Novel monoclonal antibodies for the investigation of PCH family proteins. <i>Signal Transduction</i> , 2007, 7, 320-328.	0.4	3
44	Novel synthesis of fluorochrome-coupled zoledronate with preserved functional activity on gamma/delta T cells and tumor cells. <i>MedChemComm</i> , 2015, 6, 919-925.	3.4	3